Incapta Inc
Change company Symbol lookup
Select an option...
INCT Incapta Inc
BML-J Bank of America Corp
PEP PepsiCo Inc
AGNC Agnc Investment Corp
ACM AECOM
CLSN Celsion Corp
BAC Bank of America Corp
GPHBF Graphene 3D Lab Inc(British Columbia)
ITRI Itron Inc
LTTTX MFS Lifetime 2025 Fund Class R3
Go

Communication Services : Entertainment |
Company profile

InCapta, Inc. is a media holding company. The Company is focused on the radio, television, movie production and television productions to use on online Cloud television and radio. It is developing its online movie channel, a 24 hour a day streaming Internet television station, and its online news and video news bureau in association with Leading Edge Radio Network and Mancuso Martin Productions. The Company operates two cloud television networks: World Drone Recreation Aviators and Leading Edge Radio Network. Its network develops its own channel content. It is also involved in pre-production of two full-length movies; developing a weekly half hour television show; and producing radio talk show with LeadingEdgeRadio.com.

Closing Price
$0.0001
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0002
Day's Low
0.0001
Volume
(Light)
Volume:
5,520,151

10-day average volume:
26,185,466
5,520,151

Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020

7:00 am ET October 26, 2020 (BusinessWire) Print

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results.

The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company's website at acceleronpharma.com. Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and referring to the "Acceleron Third Quarter 2020 Earnings Call."

The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.

About Acceleron

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its commercialization, research, and development efforts in hematologic and pulmonary diseases. In hematology, REBLOZYL(R) (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in North America and are also developing luspatercept for the treatment of anemia in patient populations of MDS, beta-thalassemia, and myelofibrosis. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having recently presented positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease.

For more information, please visit acceleronpharma.com. Follow Acceleron on social media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005095/en/

SOURCE: Acceleron Pharma Inc.

Investors:
Jamie Bernard, IRC, (617) 649-9650
Associate Director, Investor Relations


Media:
Matt Fearer, (617) 301-9557
Director, Corporate Communications
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.